Where are they now? Tracking down 2012's Fierce 15 A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity Amazon Care shutdown is a strategic play, not a failure, some healthcare experts say ESC 2022: AstraZeneca's Farxiga is first heart failure drug to show across-the-board mortality benefit ESC 2022: Bayer, like its rivals, hopes it made a big enough splash after phase 2 belly flop ESC 2022: Medtronic sees success with new type of implanted defibrillator ESC 2022: In conversation with Philips CMO Alexandra Gonçalves on cardiac imaging ESC 2022: Abbott’s heart pump boasts improved 5-year life expectancy for heart failure patients ESC 2022: BMS, J&J's secondary stroke med falls short in phase 2, but companies see enough potential to push forward Cigna to enter ACA exchanges in 3 more states for 2023 Alnylam clears phase 2 test for Regeneron-partnered nephropathy med, as it looks to play catch-up against Calliditas Olympus inks $3B sale of scientific tools unit to private equity firm Bain Capital Horizon charts massive biologics expansion in Ireland, where it'll add 350 new jobs CMS to devote nearly $100M to ACA navigators for 2023 open enrollment Featured Story | By Gabrielle Masson It’s the 20th year we’ve sought out the most innovative private biotechs, which also means we've entered the second decade we've been checking in on our past honorees. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner Novo Nordisk’s recent growth renaissance has flourished thanks in no small part to semaglutide—the GLP-1 molecule behind the company’s leading trio of Ozempic, Rybelsus and Wegovy. But even as the drug's metabolic empire prospers, Novo Nordisk isn’t letting its GLP-1 rest on its laurels. read more By Heather Landi Forrester healthcare analysts called the shuttering of Amazon Care "a strategic move" rather than a failure. Amazon still has its sights set on primary care, many healthcare experts say, as it represents the gatekeeper of patient care. read more By Kevin Dunleavy At the European Society of Cardiology’s annual meeting, AstraZeneca presented data that could boost Farxiga in the competitive heart failure market. It is the first heart failure drug to show it can reduce the risk of death in patients regardless of their ejection fraction status. read more By Max Bayer Bayer's anticoagulant to prevent secondary strokes flopped a phase 2 trial, keeping in line with results from rivals BMS and J&J. The company reported that its med, asundexian, did not produce a dose-dependent reduction in the composite rate of covert brain infarction or ischemic stroke. read more By Conor Hale Compared to traditional implantable defibrillators wired directly to the cardiac muscle, Medtronic's EV ICD system instead connects a single lead underneath the breastbone outside the heart. read more By Conor Hale This year’s annual meeting of the European Society of Cardiology in Barcelona carried a special spotlight on the growing power of cardiac imaging. We spoke with Alexandra Gonçalves, Philips’ chief medical officer for precision diagnosis, on how tomorrow’s technologies are providing a new view into the leading cause of death worldwide. read more By Andrea Park A heart pump from Abbott may give at least five years back to severe heart failure patients, according to clinical trial results presented this week at the 2022 European Society of Cardiology Congress in Spain. read more By Max Bayer A new interim analysis of Bristol Myers Squibb's anticoagulant milvexian as a treatment for secondary strokes shows a mixed bag of data. The drug failed its primary endpoint, but a reduction in stroke incidence among three dosing groups beat the company's expectations. read more By Paige Minemyer The expansion, which is pending regulatory approval, will bring Cigna's total ACA footprint to 363 counties across 16 states, the insurer said. read more By Gabrielle Masson After achieving its main phase 2 trial goal, Alnylam’s immunoglobulin A nephropathy (IgAN) treatment has now hit several secondary endpoints, demonstrating further potential for the Regeneron-partnered therapeutic as the companies aim to catch up to Calliditas Therapeutics' approved med Tarpeyo. read more By Andrea Park After days of swirling speculation, Olympus finally confirmed this week that it has agreed to sell off its scientific solutions business to Bain Capital Private Equity. read more By Fraiser Kansteiner Horizon has submitted a planning application to grow its development and manufacturing facility in Waterford, Ireland. The move, designed to bring on new drug substance biologics development and manufacturing firepower, will add another 320,000 square feet to the plant’s existing 44,000-square-foot fill-finish facility. read more By Robert King CMS is devoting nearly $100 million in grant funding to 59 ACA Navigator organizations, the largest amount ever given to the consumer coverage assistance program. read more Resources Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
